NasdaqGM:OABILife Sciences
OmniAb (OABI): Losses Widen 30.8% Annually, Challenging Bulls Despite 30.4% Revenue Growth Forecast
OmniAb (OABI) remains in the red, with losses climbing at an average rate of 30.8% annually over the past five years and no improvement in net profit margin. The company is expected to stay unprofitable for at least the next three years, ruling out traditional earnings growth comparisons. However, investors are eyeing a forecasted 30.4% annual revenue increase, which is well ahead of the US market's 10.5% average. With persistent unprofitability and high valuation multiples balanced against...